- Home
- BCRX vs IMNM Comparison
BCRX vs IMNM Comparison
Compare BCRX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- IMNM
- Stock Information
- Founded
- BCRX 1986
- IMNM 2006
- Country
- BCRX United States
- IMNM United States
- Employees
- BCRX N/A
- IMNM N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- BCRX Health Care
- IMNM Health Care
- Exchange
- BCRX Nasdaq
- IMNM Nasdaq
- Market Cap
- BCRX 1.4B
- IMNM 1.2B
- IPO Year
- BCRX 1994
- IMNM 2020
- Fundamental
- Price
- BCRX $7.12
- IMNM $18.67
- Analyst Decision
- BCRX Strong Buy
- IMNM Strong Buy
- Analyst Count
- BCRX 11
- IMNM 8
- Target Price
- BCRX $19.00
- IMNM $25.75
- AVG Volume (30 Days)
- BCRX 4.8M
- IMNM 1.4M
- Earning Date
- BCRX 11-03-2025
- IMNM 11-06-2025
- Dividend Yield
- BCRX N/A
- IMNM N/A
- EPS Growth
- BCRX N/A
- IMNM N/A
- EPS
- BCRX N/A
- IMNM N/A
- Revenue
- BCRX $599,816,000.00
- IMNM $9,679,000.00
- Revenue This Year
- BCRX $41.57
- IMNM N/A
- Revenue Next Year
- BCRX $6.25
- IMNM $85.36
- P/E Ratio
- BCRX N/A
- IMNM N/A
- Revenue Growth
- BCRX 45.38
- IMNM N/A
- 52 Week Low
- BCRX $6.00
- IMNM $5.15
- 52 Week High
- BCRX $11.31
- IMNM $19.16
- Technical
- Relative Strength Index (RSI)
- BCRX 51.36
- IMNM 62.73
- Support Level
- BCRX $6.71
- IMNM $17.96
- Resistance Level
- BCRX $7.17
- IMNM $19.16
- Average True Range (ATR)
- BCRX 0.26
- IMNM 1.21
- MACD
- BCRX 0.01
- IMNM 0.03
- Stochastic Oscillator
- BCRX 67.42
- IMNM 86.50
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.